ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 1577 • ACR Convergence 2022

    Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life

    Sarah Mann1, Aamir Hussain2, Anisha Dua3, Angelina Patrone4, Kalen Larson5, Peter Merkel6 and Robert Micheletti7, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Department of Dermatology, Georgetown University, Washington, DC, 3Northwestern University, Chicago, IL, 4Patient Partner, Philadelphia, PA, 5Vasculitis Foundation, Kansas City, MO, 6University of Pennsylvania, Philadelphia, PA, 7Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cutaneous manifestations of vasculitis can cause pruritus, pain, and ulceration, and their psychosocial impacts may be significant. However, the quality-of-life (QoL) impact of skin…
  • Abstract Number: 0143 • ACR Convergence 2022

    National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol

    José Luis Martín-Varillas1, Lara Sánchez-Bilbao2, Vanesa Calvo Río3, Alf Adán4, Inés Hernanz Rodríguez4, Emma Beltrán Catalán5, Sonia Castro Oreiro6, Patricia Fanlo7, Alvaro Garcia8, Ignacio Torre9, Miguel Cordero Coma10, Juan Ramón de Dios11, A. Garcia-Aparicio12, Marisa Hernandez Garfella13, Amalia Sánchez Andrade14, A. García-valle15, Olga Maiz16, Juan Roberto Miguelez Sanchez12, Sergio Rodriguez Montero17, Ana Urruticoechea18, Raul Veroz19, Arantxa Conesa20, Cristina Fernández-Carballido21, Vega Jovani Casano22, Olga Martinez23, Patricia Moya Alvarado24, Susana Romero Yuste25, Paula Rubio Muñoz26, eva Peña Sainz-Pardo27, Marta Garijo Bufort28, José Luis Hernández2 and Ricardo Blanco29, 1Hospital de Laredo, Laredo, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Valdecilla Hospital, Santander, Spain, 4H. Clinic, Barcelona, Spain, 5Hospital del Mar, Barcelona, Spain, 6H. Universitario Joan XXIII, Barcelona, Spain, 7Complejo Hospitalario de Navarra, Navarra, Spain, 8Hospital Tajo, Madrid, Spain, 9Hospital de Basurto, Basurto, Spain, 10Hospital de León, León, Spain, 11Hospital de Araba, Araba, Spain, 12Hospital Universitario de Toledo, Toledo, Spain, 13Hospital Universitario General de Valencia, València, Spain, 14Hospital Universitario Lucus Augusti, Lugo, Spain, 15Completo Asistencial Palencia, Palencia, Spain, 16Hospital Universitario de Donostia, San Sebastián, Spain, 17Virgen de Valme University Hospital, Sevilla, Spain, 18Hospital Can Misses, Ibiza, Spain, 19Hospital de Mérida, Mérida, Spain, 20Hospital Universitario de Castellón, València, Spain, 21Agencia Valenciana de Salud, Alicante, Spain, 22National Health system, Alicante, Spain, 23Hospital Clínico Universitario de Salamanca, Zamora, Spain, 24Hospital Parc Tauli, Barcelona, Spain, 25Complexo Hospitalario Universitario, Pontevedra, Spain, 26H. Esperit Sant, Barcelona, Spain, 27Hospital Universitario 12 de Octubre, Madrid, Spain, 28Hospital Sagunto, València, Spain, 29Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Adalimumab remains the only biologic approved by the EMA and FDA for the treatment of noninfectious uveitis. There are few reports on the effectiveness…
  • Abstract Number: 0466 • ACR Convergence 2022

    Assessment of Probability Scores to Predict Giant Cell Arteritis

    Chadi Sargi1, Stephanie Ducharme-Benard2, Valerie Benard3, Rosalie-Selene Meunier4, Carolyn Ross5 and Jean-Paul Makhzoum6, 1University of Montreal, Laval, Canada, 2Hopital Sacre-Coeur, Montréal, QC, Canada, 3University of Montreal, Saint-Ambroise-de-Kildare, Canada, 4Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, 5University of Montreal, Montréal, QC, Canada, 6Hopital du Sacre-Coeur de Montreal, Montréal, QC, Canada

    Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis but remains challenging to diagnose. In the past years, many probability tools have been…
  • Abstract Number: 0493 • ACR Convergence 2022

    MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center

    Matthias Froehlich1, Thorsten A. Bley2, Marc Schmalzing3, Michael Gernert1, Rudolf A. Werner4, Jost Hillenkamp5, Karl Georg Haeusler6 and Konstanze V. Guggenberger2, 1University Hospital Wuerzburg, Dpt. of Internal Medicine II, Wuerzburg, Germany, 2University Hospital Wuerzburg, Dpt. of Radiology, Wuerzburg, Germany, 3University Hospital Wuerzburg, Wuerzburg, Germany, 4University Hospital Wuerzburg, Dpt. of Nuclear medicine, Wuerzburg, Germany, 5University Hospital Wuerzburg, Dpt. of Ophtalmology, Wuerzburg, Germany, 6University Hospital Wuerzburg, Dpt. of Neurology, Wuerzburg, Germany

    Background/Purpose: Imaging techniques for the detection of mural inflammation are cornerstones in the diagnosis of giant cell arteritis (GCA). Magnetic resonance imaging (MRI) and ultrasound…
  • Abstract Number: 1081 • ACR Convergence 2022

    Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide

    Elizabeth Nettleton1, Sebastian Sattui2, Zachary Wallace3 and Mike Putman1, 1The Medical College of Wisconsin, Milwaukee, WI, 2University of Pittsburgh, Pittsburgh, PA, 3Massachusetts General Hospital, Boston, MA

    Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that may affect patients with ANCA vasculitis (AAV). Current guidelines conditionally recommend PJP prophylaxis for patients…
  • Abstract Number: 1556 • ACR Convergence 2022

    Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease

    Alba Herrero-Morant1, José Luis Martín-Varillas2, Santos Castañeda3, Olga Maiz4, Julio Sánchez-Martín5, Norberto Ortego6, Enrique Raya7, Águeda Prior-Español8, Clara Moriano9, Rafael Melero10, Genaro Graña-Gil11, Ana Urruticoechea12, Angel Ramos13, Marta Loredo-Martínez14, Eva Salgado-Pérez15, Francisca Sivera16, Ignacio Torre17, F. Javier Narváez18, Jose Luis Andreu19, Olga Martinez20, Ricardo Gómez-de la Torre21, Sabela Fernandez-Aguado22, Susana Romero Yuste23, iñigo Gonzalez-Mazon5, Carmen Alvarez Reguera5, David Martínez-López5, José Luis Hernández5, Miguel Ángel González-Gay24 and Ricardo Blanco25, 1Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 2Hospital de Laredo, Laredo, Cantabria, Spain, 3Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 4Hospital Universitario de Donostia, San Sebastián, Spain, 5Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Medicine Department, Universidad de Granada, Granada, Spain, 7Hospital San Cecilio, Granada, Spain, 8Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, 9Complejo Asistencial Universitario de León, León, Spain, 10Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 11Hospital Universitario de A Coruña, A Coruña, Spain, 12Hospital Can Misses, Ibiza, Spain, 13Complejo Hospitalario de Soria, Soria, Spain, 14Hospital Clínico Lozano Blesa, Zaragoza, Spain, 15Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, 16Hospital Universitario de Elda, San Vicente del Raspeig, Spain, 17Hospital de Basurto, Basurto, Spain, 18Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 19Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 20Hospital Clínico Universitario de Salamanca, Zamora, Spain, 21Hospital Universitario Central de Asturias, Oviedo, Spain, 22Hospital Universitario de Cabueñes, Gijon, Spain, 23Complexo Hospitalario Universitario, Pontevedra, Spain, 24Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 25Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
  • Abstract Number: 1578 • ACR Convergence 2022

    Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis

    Francis Lao1, Cal Robinson2, Megan Schlorff1, Joycelynn Ewusie3, KAREN BEATTIE1 and Michelle Batthish1, 1McMaster University, Hamilton, ON, Canada, 2The Hospital for Sick Children, Hamilton, ON, Canada, 3St Joseph's Healthcare Hamilton, Hamilton, ON, Canada

    Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
  • Abstract Number: 0146 • ACR Convergence 2022

    Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis

    Lara Sánchez-Bilbao1, Javier Loricera2, Santos Castañeda3, Clara Moriano4, F. Javier Narváez5, Vicente Aldasoro6, Olga Maiz7, Rafael Melero8, Juan Ignacio Villa9, Paloma Vela-Casampere10, Susana Romero Yuste11, José Luis Callejas12, Eugenio De Miguel13, Eva Galíndez-Agirregoikoa14, Francisca Sivera15, Jesús Carlos Fernández-López16, Carles Galisteo17, Ivan Ferraz Amaro18, Julio Sánchez-Martín1, Mónica Calderón-Goercke1, José Luis Hernández1, Miguel Ángel González-Gay19 and Ricardo Blanco2, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 4Complejo Asistencial Universitario de León, León, Spain, 5Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Hospital Universitario de Navarra, Pamplona, Spain, 7Hospital Universitario de Donostia, San Sebastián, Spain, 8Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 9Hospital Sierrallana, Torrelavega, Spain, 10Hospital General Universitario Alicante, Alicante, Spain, 11Complexo Hospitalario Universitario, Pontevedra, Spain, 12Hospital San Cecilio, Granada, Spain, 13Hospital Universitario La Paz, Madrid, Spain, 14Basurto University Hospital, Bilbao, Spain, 15Hospital Universitario de Elda, San Vicente del Raspeig, Spain, 16Complejo H. Universitario de A Coruña, A Coruña, Spain, 17Hospital Parc Tauli,, Sabadel, Spain, 18Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 19Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA). Clinical trials with TCZ in GCA were performed with intravenous (iv)…
  • Abstract Number: 0467 • ACR Convergence 2022

    All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study

    Jacob Sode1, Jens Rathmann1, Anna Wilding2, Carl Turesson3 and Aladdin Mohammad1, 1Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, 2Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

    Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…
  • Abstract Number: 0494 • ACR Convergence 2022

    Risk for Visual Loss in Patients with Giant Cell Arteritis

    Anne Bull Haaversen1, Lene Kristin Brekke2, Tanaz Kermani3, Oyvind Molberg4 and Andreas Diamantopoulos5, 1Martina Hansens Hospital, Hosle, Norway, 2Haugesund Revmatismesykehus, Haugesund, Nepal, 3University of California Los Angeles, West Hills, CA, 4Oslo University Hospital, Oslo, Nepal, 5Akershus University Hospital, Lørenskog, Norway

    Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Permanent visual loss is a feared complication reported in up to 19% of…
  • Abstract Number: 1082 • ACR Convergence 2022

    Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review

    Pratyusha Banik1, Marcia Friedman2, Daniela Ghetie3, Dongseok Choi4 and Margaret Brophy1, 1Oregon Health & Science University, Portland, OR, 2Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, 3Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Lake Oswego, OR, 4OHSU-PSU School of Public Health, Portland, OR

    Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data…
  • Abstract Number: 1557 • ACR Convergence 2022

    Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center

    Belén Atienza-Mateo1, Alfonso del Peral-Fanjul2, Veronica Pulito-Cueto3, Diana Prieto-Peña1, Miguel Ángel González-Gay4 and Ricardo Blanco5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, Spain, 3IDIVAL, Santander, Spain, 4Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Ocular and mucocutaneous manifestations of Behçet's disease (BD) are globally recognized and widely studied [Arthritis Rheumatol. 2019 Dec;71(12):2081-2089, Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl…
  • Abstract Number: 1615 • ACR Convergence 2022

    Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality

    Pavlos Stamatis1, Moman Mohammad2, David Erlinge2, Carl Turesson3, David Jayne4 and Aladdin Mohammad5, 1Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, 2Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4University of Cambridge, Cambridge, United Kingdom, 5Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden

    Background/Purpose: The deleterious effect of inflammation combined with glucocorticoid treatment may increase the risk for atherosclerotic events. The aims of this study were to investigate…
  • Abstract Number: 0433 • ACR Convergence 2022

    Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset

    Karl Gisslander1, Arthur White2, Mårten Segelmark3, Mark Little2 and Aladdin Mohammad4, 1Lund University, Lund, Sweden, 2Trinity College, Dublin, Ireland, 3Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, 4Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden

    Background/Purpose: The sub-classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been a long-standing debate. Unsupervised learning has previously been used for partitioning of phenotypic…
  • Abstract Number: 0468 • ACR Convergence 2022

    Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis

    Eugenio De Miguel1, Jose Maria Mostaza2, Carlos Lahoz2, Juan Molina3, Elisa Fernandez-Fernandez1 and Irene Monjo4, 1Hospital Universitario La Paz, Madrid, Spain, 2Hospital Carlos III, Madrid, Spain, 3Hospital General Universitario Gregorio Marañón, Madrid, Spain, 4Hospital Universitario La Paz - IdiPAZ, Madrid, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in the elderly and large vessel involvement (LV-GCA) occurs in up to 50% of cases.…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology